Recombinant alpha-1 antitrypsin (Arriva Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant alpha-1 antitrypsin (Arriva Pharmaceuticals)
Drug Alias NameSLAPI - Arriva PharmaceuticalsFusion protein (SLAPI) - ArrivaSLPI + rAAT - Arriva Pharmaceuticals
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionPeptide hydrolase inhibitors
TargetsPeptide hydrolase
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArriva Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArriva Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A